Difficult-to-Treat Spondyloarthritis in Morocco: A Real-World Study

Overview

Journal Mediterr J Rheumatol

Specialty Rheumatology

Date 2025 Feb 20

PMID 39974589

Authors

Salma Zemrani

Bouchra Amine

Imane ElBinoune

Samira Rostom

Rachid Bahiri

Affiliations

Soon will be listed here.

Abstract

Objectives: High biologic requirement in inflammatory rheumatic diseases (IRD) may indicate a difficult to treat (D2T) condition. In axial spondyloarthritis (axSpA), a consensual definition for this concept is still lacking. Our objectives are to identify the prevalence and characteristics of multiswitcher patients with axSpA, and to analyse the number and reasons for switches.

Methods: This is a longitudinal observational study including patients treated with biologic agents for axSpA. We propose to define D2T patients as those who required more than 2 b/tsDMARD. Patients who did not fulfil this definition were used as controls. The prevalence of multiswitchers was calculated, and characteristics were compared between the two groups. The number and reasons for switches were analysed in the D2T group.

Results: 124 patients were included. The prevalence of multiswitchers was 24.19%. There were no significant differences between the two groups in the age, sex, and comorbidities. D2T patients have more arthritis (p=0.01), and fibromyalgia (p=0.04), and higher disease activity before initiating biotherapy, (BASDAI:p=0.04), (ASDAS:p=0.04). Additionally, the time from diagnosis to the first use of biologic was longer (p=0.04). In the multivariate analysis, the D2T condition was found to be associated with fibromyalgia (p=0.01). Among this group, the prevalence of those treated with 3, 4, and 5 b/tsDMARD was 86%, 9%, and 5%, respectively, the primary and secondary failures were the most common reasons for switching.

Conclusion: We suggest that D2T-axSpA present several characteristics. Identification of this category in large studies is necessary to establish a consensus definition.

References

Coskun Benlidayi I . Fibromyalgia interferes with disease activity and biological therapy response in inflammatory rheumatic diseases. Rheumatol Int. 2020; 40(6):849-858. DOI: 10.1007/s00296-019-04506-2. View

Deodhar A, Yu D . Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum. 2017; 47(3):343-350. DOI: 10.1016/j.semarthrit.2017.04.005. View

Min H, Kim H, Lee S, Hong Y, Kim M, Park S . Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure. Rheumatology (Oxford). 2021; 60(12):5743-5752. DOI: 10.1093/rheumatology/keab245. View

Morrison T, Foster E, Dougherty J, Barton J . Shared decision making in rheumatology: A scoping review. Semin Arthritis Rheum. 2022; 56:152041. DOI: 10.1016/j.semarthrit.2022.152041. View

Smolen J, Braun J, Dougados M, Emery P, FitzGerald O, Helliwell P . Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2013; 73(1):6-16. PMC: 3888616. DOI: 10.1136/annrheumdis-2013-203419. View

Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou C . The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2010; 70(1):25-31. DOI: 10.1136/ard.2010.133645. View

Kohler B, Gunther J, Kaudewitz D, Lorenz H . Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. J Clin Med. 2019; 8(7). PMC: 6678427. DOI: 10.3390/jcm8070938. View

Philippoteaux C, Delepine T, Cailliau E, Philippe P, Taisne N, Pascart T . Characteristics of difficult-to-treat axial spondyloarthritis: Results of a real-world multicentric study. Joint Bone Spine. 2023; 91(2):105670. DOI: 10.1016/j.jbspin.2023.105670. View

Bello N, Etcheto A, Beal C, Dougados M, Molto A . Evaluation of the impact of fibromyalgia in disease activity and treatment effect in spondyloarthritis. Arthritis Res Ther. 2016; 18:42. PMC: 4748456. DOI: 10.1186/s13075-016-0943-z. View

10.

Wendling D, Verhoeven F, Prati C . Is the Difficult-to-Treat (D2T) concept applicable to axial spondyloarthritis?. Joint Bone Spine. 2022; 90(3):105512. DOI: 10.1016/j.jbspin.2022.105512. View

11.

Di Giuseppe D, Lindstrom U, Aaltonen K, Relas H, Provan S, Gudbjornsson B . The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. Rheumatology (Oxford). 2021; 61(9):3647-3656. DOI: 10.1093/rheumatology/keab946. View

12.

Mease P, Bhutani M, Hass S, Yi E, Hur P, Kim N . Comparison of Clinical Manifestations in Rheumatoid Arthritis vs. Spondyloarthritis: A Systematic Literature Review. Rheumatol Ther. 2021; 9(2):331-378. PMC: 8964901. DOI: 10.1007/s40744-021-00407-8. View

13.

Taitt H, Balakrishnan R . Spondyloarthritides. Emerg Med Clin North Am. 2021; 40(1):159-178. DOI: 10.1016/j.emc.2021.08.005. View

14.

Benavent D, Capelusnik D, Ramiro S, Navarro-Compan V . Looking through the window of opportunity in axial spondyloarthritis?. Joint Bone Spine. 2023; 90(6):105603. DOI: 10.1016/j.jbspin.2023.105603. View

15.

Lopez-Medina C, Molto A, Dougados M . Peripheral Manifestations in Spondyloarthritis and their Effect: An Ancillary Analysis of the ASAS-COMOSPA Study. J Rheumatol. 2019; 47(2):211-217. DOI: 10.3899/jrheum.181331. View

16.

Bruner V, Atteno M, Spano A, Scarpa R, Peluso R . Biological therapies for spondyloarthritis. Ther Adv Musculoskelet Dis. 2014; 6(3):92-101. PMC: 4040940. DOI: 10.1177/1759720X14535512. View

17.

Nagy G, Roodenrijs N, Welsing P, Kedves M, Hamar A, van der Goes M . EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2020; 80(1):31-35. PMC: 7788062. DOI: 10.1136/annrheumdis-2020-217344. View

18.

van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman R, Kameda H . Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022; 81(11):1515-1523. PMC: 9606523. DOI: 10.1136/ard-2022-222608. View

19.

Watanabe R, Okano T, Gon T, Yoshida N, Fukumoto K, Yamada S . Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems. Front Med (Lausanne). 2022; 9:1049875. PMC: 9637686. DOI: 10.3389/fmed.2022.1049875. View

20.

de Winter J, Paramarta J, de Jong H, van de Sande M, Baeten D . Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis. RMD Open. 2019; 5(1):e000802. PMC: 6340525. DOI: 10.1136/rmdopen-2018-000802. View